<DOC>
	<DOCNO>NCT00619892</DOCNO>
	<brief_summary>The primary objective study test hypothesis SSRI plus quetiapine SR ( Seroquel SR ) result superior early ( first 1-3 week treatment ) stabilization panic symptom SSRI-resistant , comorbid Panic Disorder patient versus SSRI plus placebo .</brief_summary>
	<brief_title>A Study Quetiapine SR ( Seroquel SR ) Treat SSRI-Resistant , Comorbid Panic Disorder Patients</brief_title>
	<detailed_description>This single-site , double-blind , placebo-controlled ( PLAC ) , randomize , parallel group ( 2 group ) , 8-week , quetiapine extend release ( XR ) coadministration trial . SSRI resistance determine either historically prospectively . Patients randomize remain moderately ill ( CGI-S score ≥ 4 ) . Change PDSS scale total score primary efficacy outcome measure . Responders identify ≥50 % decrease baseline PDSS score . In early week therapy , XR flexibly gradually titrate 50 400 mg/day . Conclusions : This proof-of-concept RCT support efficacy treatment strategy SSRI-resistant PD . Quetiapine XR generally well-tolerated . Important limitation small sample size , relatively low average dose quetiapine XR use .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Panic Disorder</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Provision write informed consent Diagnosis Panic Disorder DSMIV TR confirm MINI plus interview Females male age 1865 year old Female patient childbearing potential must use reliable method contraception negative urine human chorionic gonadotropin ( HCG ) test enrollment Able understand comply requirement study Have CGI illness severity score = &gt; 4 Patients comorbid major depression , dysthymia anxiety problem eligible participate well . Exclusion criterion : Pregnancy lactation Any DSMIV TR Axis I disorder mention inclusion requirement Suicidal danger self others Known intolerance quetiapine fumarate intolerance SSRI therapy Use follow cytochrome P450 3A4 inhibitor 14 day precede enrollment include limited : ketoconazole , itraconazole , fluconazole , erythromycin , clarithromycin , troleandomycin , indinavir , nelfinavir , ritonavir , fluvoxamine saquinavir Use follow cytochrome P450 inducers 14 day precede enrollment include limited : phenytoin , carbamazepine , barbiturate , rifampin , St. John 's Wort , glucocorticoid Administration depot antipsychotic injection within one dose interval ( depot ) randomization Substance alcohol dependence enrollment ( except dependence full remission , except caffeine nicotine dependence ) , define DSMIV criterion Opiates , amphetamine , barbiturate , cocaine , cannabis , hallucinogen abuse DSMIV TR criterion within 4 week prior enrollment Medical condition would affect absorption , distribution , metabolism , excretion study treatment Unstable inadequately treat medical illness ( e.g . angina pectoris , hypertension ) judge investigator Involvement planning conduct study Previous enrollment randomization treatment present study Participation another drug trial within 4 week prior enrollment study long accordance local requirement A patient diagnosis Type I Type II Diabetes Mellitus ( DM ) An absolute neutrophil count ( ANC ) 1.5 x 109 per liter A lifetime history preexist CNS/neurological disorder e.g . epilepsy , TBI , brain tumor Patient severe personality disorder Patients start new course psychotherapy ( CBT , supportive , insightoriented ) within 1 month screen visit Patients unwilling refrain participation psychotherapy 9week period study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>SSRI Resistant</keyword>
	<keyword>Seroquel SR</keyword>
	<keyword>Seroquel XR</keyword>
	<keyword>Panic Disorder</keyword>
	<keyword>Comorbid Panic Disorder</keyword>
	<keyword>Quetiapine SR</keyword>
	<keyword>Quetiapine XR</keyword>
</DOC>